查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041741

乳癌治療市場預測至2034年：按類型、癌症類型、通路、最終用戶和地區分類的全球分析

Breast Cancer Therapeutics Market Forecasts to 2034 - Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球乳癌治療市場規模將達到 379 億美元，並在預測期內以 9.3% 的複合年成長率成長，到 2034 年將達到 773 億美元。

乳癌治療是指各種旨在控制、治療或治癒乳癌的治療方法和介入措施。這些治療方法包括多種方法，例如手術、化療、放射線治療、標靶治療、荷爾蒙療法療法、免疫療法，以及精準醫療和基因療法等新興治療方法。治療方案通常根據癌症分期、特定特徵以及患者的個別健康狀況和意願而有所不同。

根據乳癌組織的統計數據，截至2022年1月，超過380萬名美國女性罹患乳癌。這些統計數據估計，2022年女性新確診癌症病例中約有30%是乳癌。

乳癌發生率增加

全球乳癌發生率的上升推動了治療方法需求的成長，並刺激了研發投入。新興技術提供了更具針對性的治療方法，提高了療效並減少了副作用。人們對早期檢測意識的提高凸顯了對綜合治療方案的需求，為市場擴張圖了有利環境。這種需求的激增透過促進價格競爭和加強合作來推動市場發展，從而改善患者照護。

藥物的副作用

乳癌藥物（例如標靶治療）的副作用可能會限制市場成長。如果出現嚴重的副作用，患者可能無法繼續使用該藥物，並可能被迫轉而接受其他類型的治療方法。治療副作用可能嚴重，並會影響患者的生活品質。

人口老化的過程

隨著全球人口老化，包括乳癌在內的癌症發生率不斷上升，導致治療方法需求日益成長。由於老化是乳癌的主要風險因素，老年人口的成長將擴大潛在患者族群。此外，老年族群對乳癌的認知不斷提高，篩檢方法不斷改進，將為早期發現和早期療育創造更多機會，從而改善治療效果並促進市場擴張。

醫療成本不斷上漲

許多進行性乳癌的治療費用昂貴，限制了缺乏足夠保險或經濟能力的患者獲得治療的機會。費用問題導致創新藥物的取得有差異，影響治療效果和患者預後。此外，高昂的費用給醫療系統帶來壓力，限制了資源，並可能限制更經濟實惠的新治療方法的研發。這些費用障礙阻礙了市場成長。

新型冠狀病毒（COVID-19）的影響：

新冠疫情擾亂了全球經濟，造成了經濟負擔和金融困難。包括醫療保健在內的許多行業都發生了巨大變化。新冠肺炎患者的住院治療被列為優先事項，其他醫療程序則延後。由於這種治療方法對許多患者來說被認為是挽救生命的，因此疫情對全球市場的影響有限。

在預測期內，標靶治療領域預計將成為最大的細分市場。

在預測期內，標靶治療領域預計將成為最大的細分市場。乳癌標靶治療能夠精準打擊癌細胞生長所需的特定分子，同時保護健康細胞。與傳統治療方法相比，標靶治療透過減少副作用和提高療效來改善患者預後。透過精確定位特定通路來阻止癌症進展的能力，能夠增強治療效果，並有望提高患者的生存率和生活品質。

在預測期內，醫院藥房細分市場預計將呈現最高的複合年成長率。

在預測期內，醫院藥房領域預計將呈現最高的複合年成長率。醫院藥局在乳癌治療中發揮著至關重要的作用，它們確保患者及時獲得專科藥物，最佳化用藥方案，並提供個人化護理。醫院藥局透過促進醫療團隊之間的順暢協作，並確保準確的藥物和治療監測，從而改善患者的治療效果。

市佔率最大的地區：

在政府措施和大型製藥公司的存在推動下，北美預計將在預測期內佔據最大的市場佔有率。該地區充滿活力，持續的研究、臨床試驗以及製藥公司與研究機構之間的合作推動創新。此外，完善的醫療基礎設施和優惠的報銷政策也為患者獲得先進治療提供了支持。

複合年成長率最高的地區：

由於多種因素，包括公眾意識的提高、技術的進步以及醫療設施可近性的改善，預計亞太地區在預測期內將保持最高的複合年成長率。此外，個人化醫療（根據特定腫瘤特徵客製化治療方法）的趨勢也不斷增強。先進診斷工具和治療方法的引入顯著改善了患者的治療效果。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球乳癌治療市場：依療法分類

  • 荷爾蒙療法
    • Aromatase抑制劑
    • 雌激素受體穩壓器（ERDs）
    • 選擇性雌激素受體調節（SERMs）
  • 標靶治療
    • 曲妥珠單抗
    • Pertuzumab
    • Everolimus
    • 阿曲妥珠單抗-美坦新
    • Palbociclib
    • 利博西克利
    • 奧拉帕尼
    • 阿貝西利
  • 化療
  • 免疫療法
  • 其他治療方法

第6章 全球乳癌治療市場：依癌症類型分類

  • HER2陽性
  • 荷爾蒙受體

第7章 全球乳癌治療市場：依通路分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章 全球乳癌治療市場：依最終用戶分類

  • 研究機構
  • 診斷中心
  • 診所
  • 其他最終用戶

第9章 全球乳癌治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Perkin Elmer Inc.
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • NanoString Technologies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb
  • Clovis Oncology
Product Code: SMRC24804

According to Stratistics MRC, the Global Breast Cancer Therapeutics Market is accounted for $37.9 billion in 2026 and is expected to reach $77.3 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Breast cancer therapeutics refers to the various treatments and interventions designed to manage, treat, or cure breast cancer. These therapeutics encompass a wide range of approaches, including surgery, chemotherapy, radiation therapy, targeted therapy, hormone therapy, immunotherapy, and newer emerging treatments like precision medicine and gene therapy. Therapeutic approaches often vary based on the stage of the cancer, its specific characteristics, and the individual patient's health and preferences.

According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The increasing prevalence of breast cancer globally prompts greater demand for therapeutic options, spurring research and development efforts. Emerging technologies offer more targeted therapies, improving efficacy and reducing side effects. The growing awareness of early detection emphasizes the need for comprehensive treatment solutions, creating a conducive environment for market expansion. This surge in demand encourages competitive pricing strategies and fosters collaborations for enhanced patient care, propelling the market forward.

Restraint:

Adverse effects of therapeutics

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. Side effects of treatments can be severe and impact the patient's quality of life.

Opportunity:

Expanding geriatric population

With an aging population worldwide, there's a higher incidence of cancer, including breast cancer, leading to a greater demand for therapeutic options. With advanced age being a primary risk factor for breast cancer, the growing demographic of older individuals creates a larger pool of potential patients. Additionally, increased awareness and improved screening methods within this population offer opportunities for early detection and intervention, fostering better treatment outcomes and market expansion.

Threat:

High cost of therapies

Many advanced breast cancer treatments are expensive, limiting access for patients without adequate insurance coverage or financial resources. Affordability issues lead to unequal access to innovative medications, impacting treatment efficacy and patient outcomes. High expenses also burden healthcare systems, constraining resources and potentially limiting research and development of newer, more accessible therapies. These cost barriers hinder the growth of the market.

Covid-19 Impact:

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. The pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients.

The targeted therapy segment is expected to be the largest during the forecast period

The targeted therapy segment is expected to be the largest during the forecast period. Targeted therapy in breast cancer offers precise treatment, attacking specific molecules crucial for cancer growth while sparing healthy cells. It enhances efficacy with reduced side effects compared to traditional treatments, improving patient outcomes. Their ability to prevent cancer's progression by pinpointing distinct pathways amplifies treatment effectiveness, promising better survival rates and a higher quality of life for patients.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies play a pivotal role in breast cancer therapeutics by ensuring timely access to specialized medications, optimizing drug regimens, and providing personalized care. They facilitate seamless coordination between healthcare teams, ensuring accurate dosing and monitoring of treatments, thereby enhancing patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to government initiatives, and the presence of key pharmaceutical companies. The region is dynamic, with ongoing research, clinical trials, and collaborations between pharmaceutical companies and research institutions driving innovation. It's also supported by strong healthcare infrastructure and favorable reimbursement policies, allowing patients access to advanced treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors, including increasing awareness, advancements in technology and improved access to healthcare facilities. There's also a growing trend toward personalized medicine, where treatments are tailored based on the specific characteristics of the tumor. The adoption of advanced diagnostic tools and treatment modalities has significantly improved patient outcomes.

Key players in the market

Some of the key players in Breast Cancer Therapeutics market include Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, Perkin Elmer Inc., Pfizer Inc., Puma Biotechnology Inc., NanoString Technologies Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Clovis Oncology.

Key Developments:

In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.

In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.

Therapies Covered:

  • Hormonal Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Other Therapies

Cancer Types Covered:

  • HER2+
  • Hormone Receptor

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

End Users Covered:

  • Research Institutions
  • Diagnostic Centers
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Therapeutics Market, By Therapy

  • 5.1 Introduction
  • 5.2 Hormonal Therapy
    • 5.2.1 Aromatase Inhibitors
    • 5.2.2 Estrogen Receptor Downregulators (ERDs)
    • 5.2.3 Selective Estrogen Receptor Modulators (SERMs)
  • 5.3 Targeted Therapy
    • 5.3.1 Trastuzumab
    • 5.3.2 Pertuzumab
    • 5.3.3 Everolimus
    • 5.3.4 Ado-Trastuzumab Emtansine
    • 5.3.5 Palbociclib
    • 5.3.6 Ribociclib
    • 5.3.7 Olaparib
    • 5.3.8 Abemaciclib
  • 5.4 Chemotherapy
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Breast Cancer Therapeutics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 HER2+
  • 6.3 Hormone Receptor

7 Global Breast Cancer Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies

8 Global Breast Cancer Therapeutics Market, By End User

  • 8.1 Introduction
  • 8.2 Research Institutions
  • 8.3 Diagnostic Centers
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Breast Cancer Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Exelixis Inc.
  • 11.2 F. Hoffmann La Roche Ltd.
  • 11.3 GlaxoSmithKline Plc
  • 11.4 Merck and Co. Inc.
  • 11.5 Sanofi
  • 11.6 Teva Pharmaceutical Industries Ltd.
  • 11.7 Viatris Inc.
  • 11.8 Novartis AG
  • 11.9 Perkin Elmer Inc.
  • 11.10 Pfizer Inc.
  • 11.11 Puma Biotechnology Inc.
  • 11.12 NanoString Technologies Inc.
  • 11.13 Daiichi Sankyo Co. Ltd.
  • 11.14 Eisai Co. Ltd.
  • 11.15 Eli Lilly and Co.
  • 11.16 AbbVie Inc.
  • 11.17 Amgen Inc.
  • 11.18 Bristol Myers Squibb
  • 11.19 Clovis Oncology

List of Tables

  • Table 1 Global Breast Cancer Therapeutics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Breast Cancer Therapeutics Market Outlook, By Therapy (2023-2034) ($MN)
  • Table 3 Global Breast Cancer Therapeutics Market Outlook, By Hormonal Therapy (2023-2034) ($MN)
  • Table 4 Global Breast Cancer Therapeutics Market Outlook, By Aromatase Inhibitors (2023-2034) ($MN)
  • Table 5 Global Breast Cancer Therapeutics Market Outlook, By Estrogen Receptor Downregulators (ERDs) (2023-2034) ($MN)
  • Table 6 Global Breast Cancer Therapeutics Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2023-2034) ($MN)
  • Table 7 Global Breast Cancer Therapeutics Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 8 Global Breast Cancer Therapeutics Market Outlook, By Trastuzumab (2023-2034) ($MN)
  • Table 9 Global Breast Cancer Therapeutics Market Outlook, By Pertuzumab (2023-2034) ($MN)
  • Table 10 Global Breast Cancer Therapeutics Market Outlook, By Everolimus (2023-2034) ($MN)
  • Table 11 Global Breast Cancer Therapeutics Market Outlook, By Ado-Trastuzumab Emtansine (2023-2034) ($MN)
  • Table 12 Global Breast Cancer Therapeutics Market Outlook, By Palbociclib (2023-2034) ($MN)
  • Table 13 Global Breast Cancer Therapeutics Market Outlook, By Ribociclib (2023-2034) ($MN)
  • Table 14 Global Breast Cancer Therapeutics Market Outlook, By Olaparib (2023-2034) ($MN)
  • Table 15 Global Breast Cancer Therapeutics Market Outlook, By Abemaciclib (2023-2034) ($MN)
  • Table 16 Global Breast Cancer Therapeutics Market Outlook, By Chemotherapy (2023-2034) ($MN)
  • Table 17 Global Breast Cancer Therapeutics Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 18 Global Breast Cancer Therapeutics Market Outlook, By Other Therapies (2023-2034) ($MN)
  • Table 19 Global Breast Cancer Therapeutics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 20 Global Breast Cancer Therapeutics Market Outlook, By HER2+ (2023-2034) ($MN)
  • Table 21 Global Breast Cancer Therapeutics Market Outlook, By Hormone Receptor (2023-2034) ($MN)
  • Table 22 Global Breast Cancer Therapeutics Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 23 Global Breast Cancer Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 24 Global Breast Cancer Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 25 Global Breast Cancer Therapeutics Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 26 Global Breast Cancer Therapeutics Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Breast Cancer Therapeutics Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 28 Global Breast Cancer Therapeutics Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 29 Global Breast Cancer Therapeutics Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 30 Global Breast Cancer Therapeutics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.